NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
Clinical Trials
50 trialsNCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed
NCT01241708 2025-09-17
(Mel/MelVel)
Hackensack Meridian Health
Phase 3 Completed
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT03234972 2024-05-29
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01788020 2024-05-13
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
University of Ulm
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT02755597 2023-08-22
Bellini
AbbVie
Phase 3 Completed
NCT01063179 2023-06-29
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01734928 2023-06-06
OPTIMISMM
Celgene
Phase 3 Completed
NCT01568866 2022-11-14
ENDEAVOR
Amgen
Phase 3 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT02495922 2021-09-10
GMMG-HD6
University of Heidelberg Medical Center
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed
NCT02811978 2019-11-08
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00722137 2018-07-12
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Takeda
Phase 3 Completed
NCT03402295 2018-01-18
GBRAM003r
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Completed
NCT01916252 2017-09-27
GEM2012MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT01910987 2017-02-17
OPTIMRETREAT
Janssen-Cilag International NV
Phase 3 Completed
NCT01324596 2016-04-15
REMoDL-B
University Hospital Southampton NHS Foundation Trust
Phase 3 Completed
NCT01530594 2016-02-25
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
King Faisal Specialist Hospital & Research Center
Phase 3 Completed
NCT00103506 2015-10-19
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01971658 2015-10-07
IFM2013-04
Nantes University Hospital
Phase 3 Completed
NCT00111748 2015-10-06
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
University of Arkansas
Phase 3 Completed
NCT00416273 2015-03-06
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00416208 2015-03-05
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00813150 2014-08-15
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT01801436 2013-05-16
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
Johnson & Johnson Taiwan Ltd
Phase 3 Completed
NCT00312845 2012-06-25
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00048230 2012-01-13
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00063726 2012-01-13
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00546780 2011-06-28
BMS TIME-1
Bristol-Myers Squibb
Phase 3 Completed
NCT00602511 2011-02-09
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Nordic Myeloma Study Group
Phase 3 Completed
NCT00093028 2010-07-02
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
University of Arkansas
Phase 3 Completed
NCT00417911 2010-06-22
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Nordic Myeloma Study Group
Phase 3 Completed
NCT00461747 2009-09-18
GEM05MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT00111319 2009-03-26
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00200681 2009-02-05
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Nantes University Hospital
Phase 3 Completed